

# Jane N Winter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11750274/publications.pdf>

Version: 2024-02-01

129  
papers

7,511  
citations

66343

42  
h-index

54911

84  
g-index

129  
all docs

129  
docs citations

129  
times ranked

7672  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	1.4	829
2	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	1.4	693
3	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
4	ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2012, 366, 399-408.	27.0	360
5	Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 4634-4642.	1.6	305
6	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	1.4	301
7	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	27.0	298
8	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. <i>Blood</i> , 2006, 107, 4207-4213.	1.4	248
9	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	1.4	242
10	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	1.6	230
11	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	206
12	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263.	3.5	142
13	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	1.6	132
14	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.0	117
15	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971.	5.5	112
16	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7331-7339.	7.0	110
17	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.4	106
18	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	1.6	102

#	ARTICLE	IF	CITATIONS
19	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1653-1659.	1.6	101
20	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	1.8	93
21	Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 589-597.	4.9	90
22	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
23	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 1318-1326.	1.4	85
24	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	4.9	81
25	Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and Long-Term Follow-Up—A Report From the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 987-987.	1.6	77
26	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	72
27	G-CSF is not necessary to maintain over 99% dose intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007, 137, 545-552.	2.5	71
28	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. <i>Cancer</i> , 1985, 56, 443-449.	4.1	68
29	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
30	Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e58491.	2.5	63
31	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	1.8	61
32	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.0	60
33	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59
34	Hypoxia-Inducible Factor-1 $\alpha$ Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	1.6	57
35	The Lactate Issue Revisited: Novel Feeding Protocols To Examine Inhibition of Cell Proliferation and Glucose Metabolism in Hematopoietic Cell Cultures. <i>Biotechnology Progress</i> , 2000, 16, 885-892.	2.6	55
36	CD23+ Mantle Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 166-177.	0.7	54

#	ARTICLE	IF	CITATIONS
37	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
38	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	5.5	48
39	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605.	7.0	48
40	Low-Grade Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 203-220.	2.5	47
41	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 385-393.	2.5	47
42	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 245-254.	4.9	45
43	Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1020-1058.	4.9	40
44	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
45	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	4.9	37
46	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	35
47	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	1.8	33
48	Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829.	4.1	32
49	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.1	29
50	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. <i>Leukemia and Lymphoma</i> , 2015, 56, 2895-2901.	1.3	28
51	Outcomes of MYC-associated lymphomas after CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	2.5	27
52	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
53	Combining Yttrium 90-Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, S22-S26.	2.1	26
54	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	7.0	25

#	ARTICLE	IF	CITATIONS
55	Inflammatory pseudotumor of the pancreas. <i>International Journal of Gastrointestinal Cancer</i> , 1995, 18, 277-283.	0.4	24
56	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
57	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	5.2	22
58	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	7.0	22
59	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.5	21
60	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	3.4	20
61	P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. <i>International Journal of Cancer</i> , 1993, 53, 804-811.	5.1	19
62	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	3.1	19
63	Evaluation of NF- $\kappa$ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.5	17
64	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	1.3	17
65	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , 2010, 150, 365-369.	2.5	16
66	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	7.0	16
67	Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e157-e162.	0.4	15
68	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4203-4203.	1.4	15
69	Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. <i>Current Opinion in Hematology</i> , 2007, 14, 360-368.	2.5	14
70	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2009, 15, 6462-6471.	7.0	14
71	Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial. <i>Blood</i> , 2021, 138, 229-229.	1.4	14
72	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , 2010, 51, 1163-1177.	1.3	13

#	ARTICLE	IF	CITATIONS
73	Current controversies in follicular lymphoma. <i>Blood Reviews</i> , 2006, 20, 179-200.	5.7	12
74	90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL. <i>Blood</i> , 2006, 108, 330-330.	1.4	12
75	NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-34.	4.9	11
76	The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience. <i>British Journal of Haematology</i> , 2018, 180, 901-904.	2.5	11
77	90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry. <i>Blood</i> , 2004, 104, 1162-1162.	1.4	11
78	Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2762-2771.	1.6	9
79	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1934-1941.	1.3	9
80	A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma. <i>Blood</i> , 2008, 112, 236-236.	1.4	9
81	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. <i>Blood</i> , 2014, 124, 3096-3096.	1.4	9
82	Follicular lymphoma: today's treatments and tomorrow's targets. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1273-1290.	1.8	7
83	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1274-1281.	4.9	7
84	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
85	Heterogeneity among the non-Hodgkin's lymphomas. implications for autologous bone marrow transplantation with in vitro Purging using monoclonal antibodies. <i>Cancer</i> , 1988, 61, 1082-1090.	4.1	6
86	A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 1000-1000.	1.4	6
87	Monoclonal antibody DLC-48: An effective reagent for use in the depletion of malignant lymphoma from human bone marrow. <i>International Journal of Cancer</i> , 1987, 39, 670-677.	5.1	5
88	Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 235-241.	2.3	5
89	Lymphocytosis, lymphadenopathy: benign or malignant?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 106-110.	2.5	5
90	Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. <i>Current Oncology Reports</i> , 2019, 21, 39.	4.0	5

#	ARTICLE	IF	CITATIONS
91	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019, 60, 3266-3271.	1.3	4
92	Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. <i>Blood</i> , 2012, 120, 548-548.	1.4	4
93	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 436-446.	0.8	3
94	Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. <i>Blood</i> , 2005, 106, 817-817.	1.4	3
95	a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 4686-4686.	1.4	3
96	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. <i>Blood</i> , 2020, 136, 9-10.	1.4	3
97	Radioimmunoconjugates in Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 299-315.	0.5	2
98	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. <i>Blood</i> , 2020, 136, 44-45.	1.4	2
99	Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis. <i>Blood</i> , 2021, 138, 231-231.	1.4	2
100	Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement. <i>Blood</i> , 2007, 109, 844-844.	1.4	1
101	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , 2009, 114, 2708-2708.	1.4	1
102	Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.. <i>Blood</i> , 2009, 114, 967-967.	1.4	1
103	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 544-544.	1.4	1
104	High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. <i>Blood</i> , 2014, 124, 3046-3046.	1.4	1
105	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 365-365.	1.4	1
106	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 143-143.	1.4	1
107	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	1.4	1
108	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020, 136, 14-16.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
110	Cachexia is an independent factor for negative clinical and functional outcomes in lymphoma patients receiving CART therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19504-e19504.	1.6	0
111	Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkinâ€™s Lymphoma (NHL): Subgroup Analyses.. <i>Blood</i> , 2004, 104, 2488-2488.	1.4	0
112	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkinâ€™s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. <i>Blood</i> , 2005, 106, 5455-5455.	1.4	0
113	Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkinâ€™s Disease (HD), Indolent Non-Hodgkinâ€™s Lymphoma (INHL) and Aggressive Non-Hodgkinâ€™s Lymphoma (ANHL).. <i>Blood</i> , 2006, 108, 3332-3332.	1.4	0
114	Hypoxia-Inducible Factor-Alpha (HIF-1 $\alpha$ ) Activation in Non-Hodgkinâ€™s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. <i>Blood</i> , 2007, 110, 3587-3587.	1.4	0
115	Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies. <i>Blood</i> , 2008, 112, 4989-4989.	1.4	0
116	The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).. <i>Blood</i> , 2009, 114, 1216-1216.	1.4	0
117	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkinâ€™s Lymphoma. <i>Blood</i> , 2011, 118, 4499-4499.	1.4	0
118	Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.. <i>Blood</i> , 2012, 120, 2751-2751.	1.4	0
119	An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.. <i>Blood</i> , 2012, 120, 2656-2656.	1.4	0
120	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012, 120, 2024-2024.	1.4	0
121	A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE <sup>®</sup> ) Therapy for Untreated â€œHigh Tumor Burdenâ€ Indolent Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2012, 120, 1642-1642.	1.4	0
122	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 213-213.	1.4	0
123	NF- $\kappa$ B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2014, 124, 1620-1620.	1.4	0
124	Average Time to Treatment in Lymphoma Patients Undergoing Ovarian Preservation: Experience from a Single Institution. <i>Blood</i> , 2015, 126, 2111-2111.	1.4	0
125	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	1.4	0
126	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3566-3566.	1.4	0
128	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
129	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	0